Saiqiao Biology showcased its scientific and technological achievements at the HICOOL 2026 summit. Domestic cell preparation equipment has now been commercialized.

On September 7, 2026, Saiqiao Biotech unveiled its self-developed CellFAB One fully automated cell preparation platform at the HICOOL 2026 Global Entrepreneurs Summit. This device integrates processes such as cell separation, activation, and amplification, enabling one-click, fully aseptic standardized production. It can be adapted to over 90% of mainstream processes, significantly reducing dependence on complex facilities and teams. Founded in 2020, Saiqiao Biotech focuses on the domesticization of upstream core equipment for CGT. It has completed the development of complete process modules and consumables, and its self-developed cell sorting columns have received more than 400 patents. Currently, its products are sold to over ten countries around the world, serving more than 100 cell therapy pipelines, with nearly 1,000 units installed, supporting the research, development, and production of domestic MSC-listed drugs and several CAR-T drugs. In 2024, the company was recognized as a national-level specialized, sophisticated, unique, and innovative “little giant” enterprise.